CN107496593A - A kind of plant extracts for treating ascites and preparation method thereof - Google Patents
A kind of plant extracts for treating ascites and preparation method thereof Download PDFInfo
- Publication number
- CN107496593A CN107496593A CN201710829415.3A CN201710829415A CN107496593A CN 107496593 A CN107496593 A CN 107496593A CN 201710829415 A CN201710829415 A CN 201710829415A CN 107496593 A CN107496593 A CN 107496593A
- Authority
- CN
- China
- Prior art keywords
- matrimony vine
- ascites
- vine extract
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003445 Ascites Diseases 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000419 plant extract Substances 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 61
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 54
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 54
- 239000000284 extract Substances 0.000 claims abstract description 50
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 48
- 201000011510 cancer Diseases 0.000 claims abstract description 42
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 19
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 19
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 19
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 19
- 239000003513 alkali Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000001354 calcination Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 238000004380 ashing Methods 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 201000009030 Carcinoma Diseases 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract description 3
- 239000002547 new drug Substances 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000033115 angiogenesis Effects 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 61
- 230000002567 autonomic effect Effects 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002968 autonomic agent Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 241000521257 Hydrops Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011603 cardia cancer Diseases 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004987 nonapoptotic effect Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000024753 bloody sputum Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of plant extracts for treating ascites and preparation method thereof.Inventor has found first through capturing for many years, confirms matrimony vine extract lockable and can optionally treat cancer ascites, matrimony vine extract is expected to the treatment cancer ascites medicine as very attractive.The mixture of medlar biological alkali and LBP-X reaches 100% to the effective percentage of cancer ascites, can treat ascites and ascites carcinoma.Possible mechanism of action is to play the effect of cancer resistance ascites by suppressing cell propagation, inducing cell apoptosis and suppressing angiogenesis.There is stronger targeting to treatment cancer ascites, drug resistance is not produced, with classic chemotherapy medicine without crossing drug resistant.Matrimony vine extract is safe and nontoxic, is expected to turn into a kind of plant new drug of new treatment cancer ascites.
Description
Technical field
The present invention relates to field of medicaments, and in particular to Plant Extracts and its preparation method and application, more particularly to
Wolfberry fruit extract and its preparation method and application.
Background technology
There is a small amount of liquid (being generally less than 200ml) under normal condition, in human abdominal cavity, lubrication is risen to intestines peristalsis.
Cause the increase of intraperitoneal amount of liquid under any pathological state, during more than 200ml, referred to as ascites (ascites).Ascites is only a kind of
Symptom, the ascitogenous cause of disease is a lot, it is relatively common have cardiovascular disease, hepatopathy, peritoneopathy, kidney trouble, dystrophia disease,
The transfer of malignant tumour peritonaeum, ovarian neoplasm, connective tissue disease etc..
Ascites cells (ascites tumor) be using tumour cell in ascites be in floating state under carry out breeding as
The tumour of feature.Belong to the most segregative liquid knurl of the same matrix of cell (being herein ascites), the obvious characteristic with malignant tumour.
Ascites tumour has two kinds, i.e., from starting to occur as soon as the tumour of ascitic type and think original solid tumor being transformed into
For the tumour of ascitic type, the former is just like yoshida sarcoma (white mouse), and the latter is just like Ai Lixishi ascites carcinomas (house mouse) and Example Ascites hepatoma
(white mouse).Ascites tumour except any period after the transfer can take ascites carry out cell individual observations sum amount calculate in addition to,
For animal because the time of tumor lethal is also short, these have many advantages in research, as tumour biological study object and control
Treating cancer basis has very big value.About the abnormal individual of chromosome number and to the repellence of cancer-resisting substance because of tumour
Species and system and difference, and each individual character can be kept by its descendant's tumour.Cancerous thoracoascites, also it is pernicious splanchnocoel
Hydrops, is one of common complication of middle and terminal cancer, and the main clinic symptoms or sign of some patientss, serious chest,
Ascites even can threat to life.The disease of Malignant Pleural is common in lung cancer, breast cancer, is secondly malignant lymphoma, oophoroma, evil
Property pleural mesothelium cancer, the cancer of the esophagus, stomach cancer, cardia cancer and agnogenic malignant tumour., can be with if ascites is than if more serious
The food of some diuresis is coordinated to take, more urinations, the help to body can be bigger.Cancerous thoracoascites, also it is pernicious splanchnocoel
Hydrops, is one of common complication of middle and terminal cancer, and the main clinic symptoms or sign of some patientss, serious chest,
Ascites even can threat to life.Surgical treatment is such as：Draw water, discharge water, efficiently control and eliminate malignant pleural and peritoneal effusion to prolonging
Long, rescue patient life has important realistic meaning.Cancerous thoracoascites are often courageous and upright, include a large amount of red white corpuscles.①
The disease of Malignant Pleural is common in lung cancer, breast cancer, is secondly malignant lymphoma, oophoroma, malignant pleural carcinoma mesothelial (mostly blood
Property hydrops), the cancer of the esophagus, stomach cancer, cardia cancer and agnogenic malignant tumour.Common sympton：Expiratory dyspnea, pectoralgia, uncomfortable in chest, gas
Asthma, cough, bloody sputum, Body weight loss, apocleisis, discomfort etc., small number of patients is originally asymptomatic.2. malignant ascite：Cause cancer ascites
Disease：Oophoroma, liver cancer, stomach cancer and cancer of pancreas.
Cancer ascites lack effective treatment method, and relatively common treatment method has intra-abdominal chemotherapy, discharge ascites etc.,
But offer limited effectiveness, the side effect of chemotherapy are bigger.
Therefore, it is badly in need of a kind of medicine of effectively treatment cancer ascites at present to solve the matter of great urgency of cancer patient.
Matrimony vine, originate from Hebei, the Inner Mongol, Shanxi, Shaanxi, Gansu, Qinghai, western Sichuan.Often it is born in height above sea level 800-3600
Ridge that rice Temperate Region in China faces south, valley floor, dry riverbed or hillside, on more gravels or sand or loess.Chinese loess
Plateau is extremely widespread.Meridian distribution of property and flavor：It is warm-natured, sour-puckery flavor；People liver, stomach, intestine and small intestine warp are nontoxic.There is matrimony vine good health care to make
Show that LBP-X has reducing blood lipid, hypoglycemic, liver protection, the antitumor and anti-ageing effect of waiting for a long time with, substantial amounts of research.
The content of the invention
It is an object of the invention to overcome the deficiencies of the prior art and provide a kind of eutherapeutic for treating cancer ascites
Wolfberry fruit extract.
It is another object of the present invention to provide a kind of medlar biological alkali and its application.
The technical solution used in the present invention is：
A kind of matrimony vine extract, its preparation method are as follows：
1) matrimony vine crushed after being dried is taken, adds 5~15 times of water, 40~70 DEG C of leachings are complete；
2) insoluble matter in leachate is removed, is dried to obtain the water extract of matrimony vine.
As the further improvement of above-mentioned matrimony vine extract, the insoluble matter in leachate is removed after separation of solid and liquid, filtrate connects
The filter membrane initial filter using 0.45 μm, is filtered again using 0.22 μm of filter membrane afterwards, further removes insoluble matter.
As the further improvement of above-mentioned matrimony vine extract, cool drying is used when drying.
Contain 60~65g medlar biological alkali in per kg matrimony vine extracts.
A kind of medlar biological alkali, its preparation method are as follows：
1) above-mentioned matrimony vine extract is taken, 500~700 DEG C of ashing are complete, obtain calcination；
2) calcination is mixed with water, stirring and dissolving, removes insoluble matter, take filtrate after refined filtration, be dried to obtain medlar biological
Alkali.
As the further improvement of above-mentioned medlar biological alkali, the operation of refined filtration is the filter membrane initial filter using 0.45 μm, afterwards
Filtered again using 0.22 μm of filter membrane.
Matrimony vine extract is preparing the application in treating cancer ascites medicine, wherein, matrimony vine extract is as described above.
A kind of medicine for treating cancer ascites, its action composition are above-mentioned matrimony vine extract.
Medicine is oral formulations.It is common that oral formulations include but is not limited to tablet, granule, capsule, oral liquid etc.
Oral formulations.Further, oral formulations are enteric oral preparation.Particularly, oral formulations are sustained release preparation.
Function is with curing mainly：It is mainly used in treating cancer ascites.
Usage and dosage：Freeze-dried powder or spray drying, granule and electuary, standard/grain 500mg, Coming-of-Age Day take 4-5 times,
Four hours clothes/time, one time 5-10 grams, 30 days courses for the treatment of, warm water auf nuechternen Magen einnehmen.
Side effect：Not it was observed that obvious toxic side effect, no drug dependence.
Taboo：Prohibit clothes during pregnant woman and lactation.
The beneficial effects of the invention are as follows：
Inventor is had found first through capturing for many years, and 60~65g matrimony vines are contained in 1000 grams of matrimony vine water extracts (dry weight)
Alkaloid, pertinent literature there is no to report so far, confirmation matrimony vine extract (mixture of medlar biological alkali and LBP-X) can be locked
Determine and can optionally treat cancer ascites, matrimony vine extract is expected to the treatment cancer ascites medicine as very attractive.Chinese holly
The mixture of Qi alkaloid and LBP-X reaches 100% to the effective percentage of cancer ascites, can treat ascites and ascites carcinoma.May
Mechanism of action be by suppress cell breed, inducing cell apoptosis and suppress angiogenesis and play cancer resistance ascites act on.
There is stronger targeting to treatment cancer ascites, drug resistance is not produced, with classic chemotherapy medicine without crossing drug resistant.Matrimony vine extract
It is safe and nontoxic, it is expected to turn into a kind of plant new drug of new treatment cancer ascites.
Matrimony vine extract has the features such as novelty, Mutiple Targets, too many levels, manifold effect is presented in treatment cancer ascites, nontoxic
Side effect etc. is furtherd investigate, and is likely to become the treatment cancer ascites new drug with clinical value.
Matrimony vine extract is a kind of most fast most rapid autonomic drug of current treatment cancer ascites, and its appearance will give treatment
Cancer ascites, which are brought, once to be broken through.It can save ten hundreds of patient vitals rapidly simultaneously, and it is oral to control cancer ascites autonomic drug
Preparation.Cytology toxicity test result shows that matrimony vine extract does not have inhibitory action substantially to normal cell, has to cancer cell
Selective killing effect.
The wolfberry fruit extract of the present invention, there is obvious inhibitory action, its IC to cancer ascites cell propagation50For S180
(17.032mg/ml), there is obvious apoptosis-promoting effect to cancer ascites cell, and there is concentration-effect relation；Can will be carcinous
The cell-cycle arrest of ascites cells is in G0/G1Phase, and there is concentration-effect relation.Carcinous abdomen can be effectively treated after oral
Water.
The medlar biological alkali extracting method of the present invention, it is high without using organic solvent, simple and safe operation, extraction efficiency,
Obtained medlar biological alkali high purity more than 99.9%.
Brief description of the drawings
Fig. 1 is absorbance curve of the matrimony vine extract aqueous solution under 200nm~600nm wavelength；
Fig. 2 is the liquid chromatogram of matrimony vine extract；
Fig. 3 is the mass spectrogram of another liquid chromatogram and its main peak of matrimony vine extract；
Fig. 4 is the HPLC chromatogram of medlar biological alkali；
Fig. 5 is concentration-inhibiting rate curve of the matrimony vine extract to S180 cells；
Fig. 6 is the influence that matrimony vine extract is bred to mouse ascites oncocyte S180；
Fig. 7 is influence of the various concentrations matrimony vine extract to mouse ascites oncocyte S180 apoptosis；
Fig. 8 is influence of the matrimony vine extract to mouse ascites oncocyte S180 apoptosis；
Fig. 9 is influence of the matrimony vine extract to the mouse ascites oncocyte S180 cell cycles.
Embodiment
Matrimony vine extracts the preparation of thing：
1) by 55~65 DEG C of crushed after being dried of matrimony vine to 80~120 mesh, the water of 5~15 times of addition, stirred at 45~55 DEG C
Mix extraction 4h；
2) insoluble matter is removed, using 0.45 μm of filter membrane initial filter, is filtered afterwards using 0.22 μm of filter membrane two, collects what is obtained
Filtrate is freeze-dried, and obtains matrimony vine extract.
Above-mentioned matrimony vine extract is taken to be detected, testing result is as shown in Figures 1 to 3.Wherein, Fig. 1 is matrimony vine extract
The aqueous solution (300mg/mL), the absorbance curve under 200nm~600nm wavelength, show that it has a peak at 283nm
Value, its absorbance is up to 1.048；Fig. 2 is the liquid chromatogram of matrimony vine extract；Fig. 3 is another liquid chromatogram of matrimony vine extract
The mass spectrogram of figure and its main peak.
After testing, 60~65g medlar biological alkali is contained in every 1000g matrimony vines extract (dry weight), surplus is LBP-X
And the impurity of very small amount (being less than 0.5%).
The extraction of medlar biological alkali：
1) foregoing extract (containing 60~65g medlar biologicals alkali in per 1000g dry weights), 500 DEG C~700 DEG C high temperature are taken
2~3h is dissolved, obtains the grey powder of charged material weight 30~35% or so；
2) grey powder is mixed with 3~4 times of water, stirring and dissolving, removes insoluble matter, obtain filtrate；
3) 0.45 μm of filter membrane initial filter is used, is filtered again using 0.22 μm of filter membrane afterwards, obtains refined filtration liquid；
4) refined filtration liquid is freeze-dried to obtain medlar biological alkali.
Medlar biological alkali is the transparent needle crystals of pure white, entrusts Shanghai Zhangjiang medicine-valley public service platform Co., Ltd
Detect its purity, test basis are Chinese Pharmacopoeia 2010 edition one, annex VID high performance liquid chromatographies.Its HPLC chromatogram is such as
Shown in Fig. 4.According to area normalization method, its main peak content is 99.93%, is a kind of high-purity extract.
With reference to experiment, technical scheme is further illustrated.
In testing below, XL-010 refers to the dried wolfberry extract that the above method is prepared.
Autonomic drug XL-010 cancer ascites cell growth inhibition check experiments
Experiment commission Hunan Province's Experimental Animal Center (Drug Safety Evaluation Center of Hunan Province) is carried out.
1 experiment material
1.1 tested material：Autonomic drug is numbered：XL-010, lot number：20170410, it is limited that the development of woods biotechnology is known by Hunan
Company provides.Autonomic drug is prepared：XL-010 9g are weighed, add 0.9% sodium chloride injection 15ml, and are vibrated to whole dissolvings,
600mg/ml plant drug solns are produced, this is maximum concentration working solution, will be standby after mother liquor progress bacteria removing.With 0.9% chlorine
Change sodium injection mother liquor is configured to 200 successively, 60,20,6,2,0.6mg/ml working solution.
1.2 positive control drug：Cis-platinum (DDP), lot number：SJJMI-IE, Tokyo HuaCheng Industry Co., Ltd；5 FU 5 fluorouracil
(5-FU), lot number：HFBM160120325008, Amresco company.Positive control drug is prepared：DDP or 5-FU2mg is weighed, with new
Fresh complete medium is configured to 100mM mother liquor, then mother liquor is configured to fresh complete medium 200 successively, 60,20,6,
2nd, 0.6 μM of working solution.
1.3 main material：
1.4 key instrument：
2 test methods
2.1 cell culture
The S180 cells covered with are taken, using the RPMI-1640 complete mediums containing 10%FBS, in 37 DEG C, 5%CO2Training
Support and cultivated in case, according to cell growth status, 1~2d is passed on or changed liquid, standby to exponential phase.
2.2CCK-8 methods detect cell proliferation test
Take the logarithm the phase growth S180 cells with every hole 5 × 103Individual cell is inoculated in 96 porocyte culture plates, culture
After 12h, vehicle control group, positive control drug (DDP) group, positive control drug (5-FU) group, autonomic drug XL-010 groups (0.3- are set
300mg/ml), every group of 5 multiple holes.Vehicle control group with fresh DMEM culture medium incubated cells completely, autonomic drug group respectively with containing
The fresh DMEM incubated cells completely of final concentration of 0.3-300mg/ml autonomic drugs, DDP and 5-FU groups are respectively with containing final concentration of
100th, the fresh DMEM incubated cells completely of 30,10,3,1,0.3 μM of autonomic drugs.By after above-mentioned processing mode incubated cell 72h
The μ l of CCK-8 10 are added in per hole, continue to cultivate the absorbance for using ELIASA to measure each hole at 450nm after 1h.With solvent pair
It is 100% cell viability according to group OD values, the ratio of remaining each group OD values and vehicle control group OD values is relative activity.Increased with cell
Grow inhibiting rate and evaluate autonomic drug to the toxicity of S180 cells, if having cell proliferation inhibition rate ＞ 100%, be judged to instrument
Systematic error, based on 100%.
The detection of 2.3 Apoptosis
2.3.1Annexin the double dye method detection Apoptosis of V-FITC and PI
The S180 cells in exponential phase are taken, conventional digestion collects cell, with 5 × 105The density in/hole is seeded to 6
In orifice plate, after cultivating 12h, vehicle control group, autonomic drug XL-010 groups (10,30,100mg/ml), every group of 5 multiple holes are set.It is molten
Matchmaker's control group is with fresh DMEM culture medium incubated cells completely, and autonomic drug group containing final concentration of 10,30,100mg/ml respectively to plant
The fresh DMEM incubated cells completely of thing medicine.After 6h, conventional digestion collects cell, adds 500 μ l Binding Buffer bufferings
Cell is resuspended in liquid, and cell is transferred in 1.5ml EP pipes, 5 μ l Annexin V-FITC, 5 μ l PI is added, in room temperature lucifuge
Under the conditions of be incubated 15min, with flow cytomery apoptosis situation.
2.3.2 fluorescence colour detects Apoptosis
Cell is handled according to 2.3.1 methods, after autonomic drug handles 6h, adds Hoechst 33342 per hole in 6 orifice plates
Dyeing liquor 1ml, fully covers cell, is placed in 37 DEG C of culture 20-30min.Dyeing liquor is discarded, glimmering after being washed 2-3 times with PBS
Fluoroscopic examination is carried out under light microscope.
Influence of the 2.4 Flow cytometry autonomic drugs to the mouse ascites oncocyte S180 cycles
The S180 cells in exponential phase are taken, conventional digestion collects cell, with 5 × 105The density in/hole is seeded to 6
In orifice plate, after 12h cell attachments, vehicle control group, autonomic drug XL-010 groups (100,30,10mg/ml) be set, every group 5
Multiple holes.Vehicle control group with fresh DMEM culture medium incubated cells completely, autonomic drug group respectively with containing final concentration of 10,30,
The fresh DMEM incubated cells completely of 100mg/ml autonomic drugs.After 6h, conventional digestion collects cell, is fixed with 70% cold ethanol
At night, add 5 μ l PI, room temperature lucifuge is incubated 30min, with the flow cytomery cell cycle.
2.5 statistical analysis
Data are handled using the statistical softwares of SPSS 16.0, measurement data withRepresent, the ratio of two sample averages
Examined compared with using Student T-Test, the comparison of mean is using One-way ANOVA inspections, P between multisample group<0.05 represents
It is statistically significant, P<0.01 represents that examined difference is very significant.
Evaluation of result
The influence that 3.1 autonomic drug XL-010 breed to mouse ascites oncocyte S180
After the autonomic drug processing cell of micro- Microscopic observation various concentrations, there is cell proliferation rate and slow down, cell fragment
Increase, space between cells increases, phenomena such as shape of sand vacuole occurs in cell.Incubation time has clear and definite correlation to cell state together,
About after 12h is co-cultured, being rounded occurs in cell, the phenomenon of shrinkage；After 24h is co-cultured, there is part cell and swell, cell is saturating
Photosensitiveness is deteriorated, intercellular gap increase；After 48h is co-cultured, there is shape of sand vacuole in cell, the situations such as cell rupture occurs；
After 72h is co-cultured, shape of sand vacuole like cell substantially completely ruptures, without complete under 300,100,30mg/ml concentration conditions
The cell of cellular morphology, only see and be condensed into stain shape on a small quantity.Cell co-cultures with test sample or positive control drug DDP and 5-FU
After 72h, cell propagation is substantially suppressed, and has concentration-effect relation, with significant difference compared with vehicle control group
(P<0.01).Cell inhibitory effect is the results detailed in Table 1.
The influence that table 1, autonomic drug XL-010 breed to mouse ascites oncocyte S180
Note：* represent compared with vehicle control group, P<0.05, * * expressions are compared with vehicle control group, P<0.01.IC50Represent
Suppress the concentration of 50% tumour cell, Emax represents the maximal percentage inhibition to tumour cell.
XL-010 is as shown in Figure 5 to concentration-inhibiting rate curve of S180 cells.
Autonomic drug XL-010 shows that influence such as Fig. 6 that mouse ascites oncocyte S180 breeds arrow represents non-viable non-apoptotic cell.From
It can be seen from the figure that, autonomic drug XL-010 can promote mouse ascites oncocyte S180 downright bad well.
Influences of the 3.2 autonomic drug XL-010 to mouse ascites oncocyte S180 apoptosis
Use concentration for 10,30, after 100mg/ml autonomic drug intervenes mouse ascites oncocyte S180 6h, collect cell,
Apoptosis is detected after the double dyes of Annexin V-FITC/PI.Cell after double dyes can be divided into 4 groups by flow cytometer：Q1-UL generations
Table mechanical damage cell (Annexin V-/PI+)；Q1-UR non-viable apoptotic cells (Annexin V+/PI+)；Q1-LL survivals are thin
Born of the same parents (Annexin V-/PI-)；Q1-LR viable apoptotic cells (Annexin V+/PI-).
The influence of table 2, autonomic drug XL-010 to mouse ascites oncocyte S180 apoptosis
Note：* represent compared with vehicle control group, P<0.05, * * expressions are compared with vehicle control group, P<0.01.
As a result show：The S180 cells late apoptic and non-viable non-apoptotic cell number handled through autonomic drug XL-010 is apparently higher than solvent
Control group (P<0.05), and there is concentration-effect relation.
Influences of the various concentrations autonomic drug XL-010 to mouse ascites oncocyte S180 apoptosis is as shown in fig. 7, in figure, A is
Vehicle control group, B are autonomic drug 10mg/ml groups, and C is autonomic drug 30mg/ml groups, and D is autonomic drug 100mg/ml groups.
Influences of the autonomic drug XL-010 to mouse ascites oncocyte S180 apoptosis is as shown in figure 8, arrow represents nucleus wrinkle
Contracting, prompts for apoptotic cell.It can clearly be seen that XL-010 can promote mouse ascites oncocyte S180 apoptosis from figure.
Influences of the 3.3 autonomic drug XL-010 to the mouse ascites oncocyte S180 cycles
Use concentration for 10,30, after 100mg/ml autonomic drug intervenes mouse ascites oncocyte S180 24h, collect thin
Born of the same parents, after being fixed with 70% cold ethanol, after PI dyeing, the flow cytometry analysis cell cycle.Experimental result is as shown in table 3：
The influence of table 3, autonomic drug XL-010 to the mouse ascites oncocyte S180 cell cycles
Note：* represent compared with vehicle control group, P<0.05, * * expressions are compared with vehicle control group, P<0.01
As a result show：After using autonomic drug XL-010, G0/G1Cell proportion substantially increases, G2/ M phase ratios substantially subtract
It is few, show that mouse ascites oncocyte S180 is mainly arrested in G by it to mouse ascites oncocyte S180 inhibited proliferations0/G1
Phase, it is prevented to enter the S phases.
As shown in figure 9, in figure, A is solvent for influences of the autonomic drug XL-010 to the mouse ascites oncocyte S180 cell cycles
Control group, B are autonomic drug 10mg/ml groups, and C is autonomic drug 30mg/ml groups, and D is autonomic drug 100mg/ml groups.
4 conclusions are with discussing
In summary, under this experiment condition, autonomic drug XL-010 can significantly inhibit a kind of mouse ascites oncocyte S180 and increase
Grow, and there is concentration-effect relation, under a high concentration condition, with the extension of time, cancer cell can be killed completely, its
Can be by cell-cycle arrest in G0/G1Phase, inducing cell apoptosis.This autonomic drug performance suppression cancer cell concentration is higher, is mg/ml
Level, may be related to its distinctive mechanism of action.
Described above is only the preferred embodiment of the present invention, it is noted that for the common skill of the art
For art personnel, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications
Also within protection scope of the present invention.
Claims (10)
1. a kind of matrimony vine extract, its preparation method are as follows：
1) matrimony vine crushed after being dried is taken, adds 5~15 times of water, 40~70 DEG C of leachings are complete；
2) insoluble matter in leachate is removed, is dried to obtain the water extract of matrimony vine.
2. matrimony vine extract according to claim 1, it is characterised in that：Removed after separation of solid and liquid insoluble in leachate
Thing, filtrate are then used 0.45 μm of filter membrane initial filter, are filtered, further removed insoluble again using 0.22 μm of filter membrane afterwards
Thing.
3. matrimony vine extract according to claim 1 or 2, it is characterised in that：Cool drying is used when drying.
4. matrimony vine extract according to claim 1 or 2, it is characterised in that：Contain 60~65g in per kg matrimony vine extracts
Medlar biological alkali.
5. a kind of medlar biological alkali, its preparation method are as follows：
1) the matrimony vine extract described in claims 1 to 33 is taken, 500~700 DEG C of ashing are complete, obtain calcination；
2) calcination is mixed with water, stirring and dissolving, removes insoluble matter, take filtrate after refined filtration, be dried to obtain medlar biological alkali.
A kind of 6. medlar biological alkali according to claim 5, it is characterised in that：The operation of refined filtration is the filter using 0.45 μm
Film initial filter, filtered again using 0.22 μm of filter membrane afterwards.
7. matrimony vine extract is preparing the application in treating cancer ascites medicine, it is characterised in that：Matrimony vine extract such as right will
Ask described in 1~3 any one.
A kind of 8. medicine for treating cancer ascites, it is characterised in that：Its action composition is described in any one of Claims 1 to 4
Matrimony vine extract.
9. medicine according to claim 7, it is characterised in that：Medicine is oral formulations.
10. medicine according to claim 8, it is characterised in that：Oral formulations are enteric oral preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710829415.3A CN107496593A (en) | 2017-09-14 | 2017-09-14 | A kind of plant extracts for treating ascites and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710829415.3A CN107496593A (en) | 2017-09-14 | 2017-09-14 | A kind of plant extracts for treating ascites and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107496593A true CN107496593A (en) | 2017-12-22 |
Family
ID=60696642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710829415.3A Pending CN107496593A (en) | 2017-09-14 | 2017-09-14 | A kind of plant extracts for treating ascites and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496593A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6087772A (en) * | 1983-10-18 | 1985-05-17 | Zengoro Kikuta | Natural agent |
| CN1100324A (en) * | 1994-04-28 | 1995-03-22 | 福州昌江生化技术研究所 | Lycium chinense oral liquid and its preparing method |
| CN107136370A (en) * | 2017-05-09 | 2017-09-08 | 天津岂均生物科技有限公司 | A kind of herb fermenting beverage with antitumor efficacy and preparation method thereof |
-
2017
- 2017-09-14 CN CN201710829415.3A patent/CN107496593A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6087772A (en) * | 1983-10-18 | 1985-05-17 | Zengoro Kikuta | Natural agent |
| CN1100324A (en) * | 1994-04-28 | 1995-03-22 | 福州昌江生化技术研究所 | Lycium chinense oral liquid and its preparing method |
| CN107136370A (en) * | 2017-05-09 | 2017-09-08 | 天津岂均生物科技有限公司 | A kind of herb fermenting beverage with antitumor efficacy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 罗建宁等: "枸杞精抗恶性肿瘤作用的研究", 《现代应用药学》 * |
| 谭军等: "枸杞水浸提条件的探讨", 《华中农业大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038690B (en) | Application of bufarenogin to preparing antitumor medicinal preparation | |
| Zeng et al. | Laminaria japonica polysaccharides effectively inhibited the growth of nasopharyngeal carcinoma cells in vivo and in vitro study | |
| CN103877101A (en) | Application of cucurbitacine in preparation of antitumour medicament | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN104707097B (en) | Pharmaceutical composition Mongolian oak stilbene dissipates and its application in the drug for blocking hepatic precancerosis, treatment liver cancer or virus hepatitis is prepared | |
| CN105541562B (en) | Sesquiterpene quinone compound Dysiherbols A and preparation method and application thereof | |
| CN102225198B (en) | Anti-tumour medicine composition and preparation method and application thereof | |
| CN107496593A (en) | A kind of plant extracts for treating ascites and preparation method thereof | |
| CN101791363B (en) | Broad spectrum anticancer vegetable drug, preparation method and application thereof | |
| CN107137416B (en) | A kind of pharmaceutical composition preventing and treating non-small cell lung cancer | |
| CN101569654B (en) | Application of pigeon pea stilbene acid in the preparation of antitumor drug | |
| CN103919850B (en) | A kind of pharmaceutical composition and its application in antineoplastic is prepared | |
| CN102580065A (en) | Ornithogalum caudatum saponin OSW-1 oral anticancer preparation and preparation method thereof | |
| CN107550952A (en) | A kind of plant extracts for treating infiltration ductal carcinomas of breast and preparation method thereof | |
| CN105796518B (en) | A kind of diosbulbin B dispersible tablet and preparation method thereof | |
| CN110585287A (en) | Application of Nauclea officinalis extract in preparation of antitumor drugs | |
| CN109172549A (en) | A kind of anti-tumor activity composition and its application | |
| CN102579821B (en) | Medicine composition for treating lung cancer and preparation method thereof | |
| CN107582565A (en) | A kind of medicine of targeted therapy of lung cancer and its application | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN107669699A (en) | A kind of medicine for treating colon cancer and its application | |
| CN107510700A (en) | A kind of medicine of targeted therapy carcinoma of urinary bladder and its application | |
| CN106038531A (en) | Application of chlorogenic acid to induction of HepG2 cell apoptosis | |
| CN101099769B (en) | Application of Fructus Forsythiae in preparing anti-tumor chemotherapeutic sensitivity intensifying attenuating medicine | |
| CN107551011A (en) | A kind of plant extracts for treating metastasis of cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171222 |
|
| RJ01 | Rejection of invention patent application after publication |